Prof Gert Attard (UCL Cancer Institute, London, UK) chairs a panel discussion with Dr Lynda Corrigan (Tallaght University Hospital, Dublin, Ireland), Dr Jochen Walz (Institut Paoli-Calmettes Cancer Centre, Marseille, France) and Prof Wolfgang Fendler (Universitätsklinikum Essen, Essen, Germany) on precision oncology and testing for prostate cancer.

The panel look at the latest developments in personalised, patient-centric treatment strategies for PSMA-PET positive mHSPC patients.

They also examine testing disparities and unmet needs in mCRPC, focusing on optimising targeted therapies, particularly for BRCA mutation carriers, through early testing and personalised selection.